Influence of Cyp2D6 genetic polymorphism on ratios of steady-state serum concentration to dose of the neuroleptic zuclopenthixol

Therapeutic Drug Monitoring

Volumn 18, Issue 6, 1996, Pages 629-634

  Linnet, Kristian ^a   Wiborg, Ove ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cyp2D6; Serum concentrations; Zuclopenthixol

Indexed keywords

CYTOCHROME P450 ISOENZYME; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; ZUCLOPENTHIXOL;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; FEMALE; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; CLOPENTHIXOL; CYTOCHROME P-450 CYP2D6; DENMARK; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 0029805032     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199612000-00001     Document Type: Article

References (19)

1. Dahl M-L, Bertilsson L. Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics 1993;3:61-70.
2. Dahl-Puustinen M-L, Lidén A, Alm C, Nordin C, Bertilsson L. Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clin Pharmacol Ther 1989;46:78-81.
3. Dahl M-L, Ekqvist B, Widén J, Bertilsson L. Disposition of the neuroleptic zuclopenthixol cosegregtes with the polymorphic hydroxylation of debrisoquine in humans. Acta Psychiatri Scand 1991;84:99-102.
4. von Bahr C, Movin G, Nordin C, et al. Plasma levels of thioridazine and metabolites are influenced by the debrisoquine hydroxylation phenotype. Clin Pharmacol Ther 1991; 49:234-40.
5. Llerena A, Alm C, Dahl M-L, Ekqvist B, Bertilsson L. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit 1992;14:92-7.
6. Llerena A, Dahl M-L, Ekqvist B, Bertilsson L. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. Ther Drug Monit 1992;14:261-4.
7. Aaes-Jørgensen T, Gravem A, Jørgensen A. Serum levels of the isomers of clopenthixol in patients given cis(Z)-clopenthixol or cis(Z)/trans(E)-clopenthixol. Acta Psychiatr Scand 1981;64(suppl 294):70-7.
8. Heim MH, Meyer VA. Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 1990;336:529-32.
9. Spurr NK, Gough AC, Dale Smith CA, Wolf CR. Genetic analysis of cytochrome P450 system. Meth Enzymol 1991; 206:149-66.
10. Tyndale R, Aoyama T, Broly F, et al. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Pharmacogentics 1991;1:26-32.
11. Yokota H, Tamura S, Furuya H, et al. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics 1993;3:256-63.
12. Aaes-Jørgensen T. Specific high-performance liquid chromatographic method for estimation of the cis(Z)- and trans(E)-isomers of clopenthixol and a N-dealkyl metabolite. J Chromatogr 1980;183:239-45.
13. Alvan G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990;39:533-7.
14. Licht RW, Thomsen K, Diesen OV, Poulsen JH. Interindividual variation in serum zuclopenthixol and perphenazine concentrations in orally treated patients. Nord J Psychiatry 1994;48:173-5.
15. Dawson E, Powell JF, Nöthen MM, et al. An association study of debrisoquine hydroxylase (CYP2D6) polymorphisms in schizophrenia. Psychiatr Genet 1994;4:215-8.
16. Johansson I, Lundqvist E, Bertilsson L, Dahl M-L, Sjöqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993;90:11825-9.
17. Linnet K. Comparison of the kinetic interactions of the neuroleptics perphenazine and zuclopenthixol with tricyclic antidepressives. Ther Drug Monit 1995;17:308-11.
18. Meyer JW, Woggon B, Baumann P, Meyer UA. Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type. Eur J Clin Pharmacol 1990;39:613-4.
19. Arthur H, Dahl M-L, Siwers B, Sjöqvist F. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J Clin Psychopharmacol 1995;15:211-6.